Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30
Oppenheimer analyst Jeff Jones maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the price target from $32 to $30.
Stocks · News reference
MediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M vs $24.125M Est
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million vs $24.125 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MediWound Q2 2026 Earnings Call: Complete Transcript
MediWound (NASDAQ:MDWD) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
MediWound Q2 EPS $(0.77) Misses $(0.76) Estimate, Sales $3.092M Beat $2.588M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.76) by 1.32 percent. This is a 37.4 percent increase over losses of $(1.23) per share from the